New Data on Welshite, e.g. Ca2Mg3.8Mn0.62+Fe0.12+Sb1.55+O2 [Si2.8Be1.7Fe0.653+Al0.7As0.17O18], an Aenigmatite-Group Mineral

Electron and ion microprobe data on two samples of welshite from the type locality of Langban, Sweden, gave analytical totals of 99.38-99.57 wt.% and BeO contents of 4.82-5.11 wt.%, corresponding to 1.692-1.773 Be/20 O. Mossbauer and optical spectra of one of these samples gave Fe-[iv](3+)/Sigma Fe = 0.91, Fe-[iv](2+)/Sigma Fe = 0.09, and no evidence of Mn3+. The resulting formula for this sample is Ca2Mg3.8Mn0.62+Fe0.12+Sb1.55+O2[Si2.8Be1.7Fe0.653+Al0.7As0.17O18], and that for the second sample, Ca2Mg3.8Mn0.12+Fe0.12+F0.83+Sb1.25+O2[Si2.8Be1.8F0.653+Al0.25As0.25O18], is related by the substitution involving tetrahedral and octahedral sites: 0.59([vi,iv])(Fe,Al)(3+) approximate to 0.42([vi])(Mg,Mn,Fe)(2+) + 0.21(Sb-[vi],As-[iv])(5+), i.e. 3([vi,iv]) M3+ = 2([vi])M(2+) + M-[vi,iv](5+). WelShite is distinctive among aenigmatite-group minerals in the high proportion of Fe 3+ in tetrahedral coordination and is unique in its Be content, substantially exceeding 1Be per formula unit. Given the cation distributions in other minerals related to aenigmatite, we think it is reasonable to assume that at least one tetrahedral site is >50% occupied by Be and that one octahedral site is >50% occupied by Sb, so that welshite should be retained as a distinct species with its own name in the aenigmatite group.

Ms. Barth. 62 - Sammelhandschrift

Vorbesitzer: Jakob Rudesheim; Bartholomaeusstift Frankfurt am Main

Ms. Praed. 62 - Collectarius super librum Psalmorum

Vorbesitzer: Dominikanerkloster Frankfurt am Main

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years, nonvertebral fracture rates significantly decreased in years 4-7 versus years 1-3. This is the first demonstration of a further benefit on fracture outcomes with long-term therapy for osteoporosis. INTRODUCTION This study aimed to evaluate whether denosumab treatment continued beyond 3 years is associated with a further reduction in nonvertebral fracture rates. METHODS Participants who completed the 3-year placebo-controlled Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) study were invited to participate in an open-label extension. The present analysis includes 4,074 postmenopausal women with osteoporosis (n = 2,343 long-term; n = 1,731 cross-over) who enrolled in the extension, missed ≤1 dose during their first 3 years of denosumab treatment, and continued into the fourth year of treatment. Comparison of nonvertebral fracture rates during years 1-3 of denosumab with that of the fourth year and with the rate during years 4-7 was evaluated. RESULTS For the combined group, the nonvertebral fracture rate per 100 participant-years was 2.15 for the first 3 years of denosumab treatment (referent) and 1.36 in the fourth year (rate ratio [RR] = 0.64; 95 % confidence interval (CI) = 0.48 to 0.85, p = 0.003). Comparable findings were observed in the groups separately and when nonvertebral fracture rates during years 1-3 were compared to years 4-7 in the long-term group (RR = 0.79; 95 % CI = 0.62 to 1.00, p = 0.046). Fracture rate reductions in year 4 were most prominent in subjects with persisting low hip bone mineral density (BMD). CONCLUSIONS Denosumab treatment beyond 3 years was associated with a further reduction in nonvertebral fracture rate that persisted through 7 years of continuous denosumab administration. The degree to which denosumab further reduces nonvertebral fracture risk appears influenced by the hip bone density achieved with initial therapy.

Gottvertrauen : Nach dem 62. Psalm (Gedicht)

Abraham Levi

Ms. hebr. oct. 62 Film - Sefer ha-galgal

Vorbesitzer: Shemʾuel ben Shimʹon; Hirsch Scheuer; Abraham Merzbacher

Na 50 Nachlass Arthur Schopenhauer - 'Schopenhauer-Archiv', 62 - Kritische Äußerungen zu den Finanzgeschäften des Bankhauses Muhl

u.a.: Verzinsung von Kapital; Geschäfte mit Staatspapieren; Geldverleih an Anthime Gregoire de Blésimaire; Briefwechsel zur Mutter Johanna Schopenhauer; Joachim Wilhelm von Weickelmann; Bihl; H. Croulen;

Na 50 Nachlass Arthur Schopenhauer - 'Schopenhauer-Archiv', 343 - Anmerkungen an Professor Hugo von Meltzl zum Baufortschritt des Schopenhauer-Denkmals

u.a.: Schopenhauer Denkmal; Anti-Schopenhauerismus; Ferdinand Laban; Arthur Schopenhauer;

Ms.Ff.F.Stoltze 3. 62 - Brief von Rudolf Fendt an Friedrich Stoltze

Persönliche Nachrichten, Ernst Emmerling, Leopold Sonnemann

Ms. hebr. oct. 62 - Sefer ha-galgal

Vorbesitzer: Shemʾuel ben Shimʹon; Hirsch Scheuer; Abraham Merzbacher;